CA3022195C - Compounds for modulating aquaporins - Google Patents

Compounds for modulating aquaporins Download PDF

Info

Publication number
CA3022195C
CA3022195C CA3022195A CA3022195A CA3022195C CA 3022195 C CA3022195 C CA 3022195C CA 3022195 A CA3022195 A CA 3022195A CA 3022195 A CA3022195 A CA 3022195A CA 3022195 C CA3022195 C CA 3022195C
Authority
CA
Canada
Prior art keywords
thiadiazol
triazol
acetamide
ethy1
pheny1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3022195A
Other languages
English (en)
French (fr)
Other versions
CA3022195A1 (en
Inventor
Johan Evenas
Joakim Larsson
Klaus DREISCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apoglyx AB
Original Assignee
Apoglyx AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apoglyx AB filed Critical Apoglyx AB
Publication of CA3022195A1 publication Critical patent/CA3022195A1/en
Application granted granted Critical
Publication of CA3022195C publication Critical patent/CA3022195C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3022195A 2016-04-28 2017-04-28 Compounds for modulating aquaporins Active CA3022195C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167378 2016-04-28
EP16167378.5 2016-04-28
PCT/EP2017/060148 WO2017186893A1 (en) 2016-04-28 2017-04-28 Compounds for modulating aquaporins

Publications (2)

Publication Number Publication Date
CA3022195A1 CA3022195A1 (en) 2017-11-02
CA3022195C true CA3022195C (en) 2024-02-13

Family

ID=55854711

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3022195A Active CA3022195C (en) 2016-04-28 2017-04-28 Compounds for modulating aquaporins

Country Status (12)

Country Link
US (1) US10730865B2 (enExample)
EP (1) EP3448853B1 (enExample)
JP (1) JP6921118B2 (enExample)
CA (1) CA3022195C (enExample)
DK (1) DK3448853T3 (enExample)
ES (1) ES2902409T3 (enExample)
HR (1) HRP20212031T1 (enExample)
HU (1) HUE057193T2 (enExample)
LT (1) LT3448853T (enExample)
PL (1) PL3448853T3 (enExample)
PT (1) PT3448853T (enExample)
WO (1) WO2017186893A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393444B (zh) * 2019-01-02 2022-10-28 上海迪赛诺化学制药有限公司 一种阿巴卡韦羟基醋酸酯的制备方法
WO2025137265A1 (en) 2023-12-20 2025-06-26 Saint Michael's College, Inc. Methods and compositions for reducing gliaptosis: macroglia-induced neuronal cell death
CN118001408B (zh) * 2024-04-08 2024-06-25 北京大学 一种水通道蛋白9磷酸化抑制剂的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US333792A (en) * 1886-01-05 Stop watch
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
GB0704394D0 (en) * 2007-03-07 2007-04-11 Senexis Ltd Compounds
JP6671382B2 (ja) 2014-10-29 2020-03-25 アポグリクス アクツィエブーラーグＡｐｏＧｌｙｘ ＡＢ 特に糖尿病の治療に有用である２−（１，２，４−トリアゾール−３−イルスルファニル）−ｎ−１，３，４−チアジアゾール−２−イルアセトアミドの誘導体

Also Published As

Publication number Publication date
LT3448853T (lt) 2022-01-10
HRP20212031T1 (hr) 2022-04-01
JP2019516677A (ja) 2019-06-20
ES2902409T3 (es) 2022-03-28
PL3448853T3 (pl) 2022-02-28
HUE057193T2 (hu) 2022-04-28
JP6921118B2 (ja) 2021-08-18
EP3448853B1 (en) 2021-11-17
PT3448853T (pt) 2021-12-30
US10730865B2 (en) 2020-08-04
WO2017186893A1 (en) 2017-11-02
US20190127360A1 (en) 2019-05-02
DK3448853T3 (da) 2021-12-06
EP3448853A1 (en) 2019-03-06
CA3022195A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
ES2526675T3 (es) N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2023066371A1 (zh) 含氮的四环化合物、其制备方法及其在医药上的应用
CN105339368B (zh) 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
CN103153968B (zh) 三唑衍生物及含有其的具有镇痛作用的药物组合物
HUE030519T2 (en) Pyridazinone derivatives
CN110603254A (zh) 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
US12599582B2 (en) Pyrrole compounds
KR20110104558A (ko) 설폰아미드 유도체
IL285246B2 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
US10730865B2 (en) Compounds for modulating aquaporins
TW201443025A (zh) 化學化合物
AU2015340613B2 (en) Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes
CN102558167A (zh) Gk和ppar双重激动活性的噻唑烷二酮衍生物
JP2025511160A (ja) ピラゾロピラジノン化合物、その調製のための方法及びその治療的使用
OA22136A (en) Pyrrole compounds.
HK1161253B (en) Sulfonamide derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220426

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250303

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250303

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260302

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260302